VEGFA and neoplasm: The inhibition of VEGF-induced neovascularization by lenvatinib facilitates the infiltration of immune cells into the tumor, decreases the presence of suppressive TAMs and Tregs (check when abbreviation first occurs), enhances dendritic cell activity, and increases the release of pro-inflammatory cytokines [182].